Basic Information
| ID | DRAMP21388 |
|---|
| Sequence | RWIRWVWRKKLR |
|---|
| Length | 12 |
|---|
| Name | SP15 * (De Novo Synthesis) |
|---|
| Source | synthetic construct |
|---|
| Activity | Antimicrobial, Antibacterial, Anti-Gram- |
|---|
| Pathogen | [Ref.31163671] Gram-negative bacteria:Escherichia coli ATCC 25922 (MIC= 3.125–6.25 µg/mL) |
|---|
| Hemolytic Activity | [Ref.31163671] 10% hemolysis at >100 μg/mL against human blood cells. |
|---|
| Cytotoxicity | [Ref.31163671] The cell viability of Hepa 1-6 induced by SP15 is 90.5%, 90.5%, 89.2%, 83.1%, 93.2% and 52.7% at peptide concentrations of 3.125, 6.25, 12.5, 25, 50 and 100 μg/mL. |
|---|
| N-terminal Modification | Free |
|---|
| C-terminal Modification | Amidation |
|---|
| Linear/Cyclic/Branched | Linear |
|---|
| Uniprot |
|
|---|
| PDB |
|
|---|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 31163671 |
|---|
